» Articles » PMID: 36302886

Development of Lipid Nanoparticles and Liposomes Reference Materials (II): Cytotoxic Profiles

Overview
Journal Sci Rep
Specialty Science
Date 2022 Oct 27
PMID 36302886
Authors
Affiliations
Soon will be listed here.
Abstract

Lipid based nanocarriers are one of the most effective drug delivery systems that is evident from the recent COVID-19 mRNA vaccines. The main objective of this study was to evaluate toxicity of six lipid based formulations with three surface charges-anionic, neutral or cationic, to establish certified reference materials (CRMs) for liposomes and siRNA loaded lipid nanoparticles (LNP-siRNA). Cytotoxicity was assessed by a proliferation assay in adherent and non-adherent cell lines. High concentration of three LNP-siRNAs did not affect viability of suspension cells and LNP-siRNAs were non-toxic to adherent cells at conventionally used concentration. Systematic evaluation using multiple vials and repeated test runs of three liposomes and three LNP-siRNA formulations showed no toxicity in HL60 and A549 cells up to 128 and 16 µg/mL, respectively. Extended treatment and low concentration of LNPs did not affect the viability of suspension cells and adherent cells at 96 h. Interestingly, 80% of A549 and HL60 cells in 3D conditions were viable when treated with cationic LNP-siRNA for 48 h. Taken together, anionic, cationic and neutral lipid formulations were non-toxic to cells and may be explored further in order to develop them as drug carriers.

Citing Articles

Nanoscale reference and test materials for the validation of characterization methods for engineered nanomaterials - current state, limitations, and needs.

Abram S, Tavernaro I, Johnston L, Zou S, Resch-Genger U Anal Bioanal Chem. 2025; .

PMID: 39754617 DOI: 10.1007/s00216-024-05719-6.


Endosomal escape mechanisms of extracellular vesicle-based drug carriers: lessons for lipid nanoparticle design.

Hagedorn L, Jurgens D, Merkel O, Winkeljann B Extracell Vesicles Circ Nucl Acids. 2024; 5(3):344-357.

PMID: 39697635 PMC: 11648457. DOI: 10.20517/evcna.2024.19.


Liposomal Formulations of Novel BODIPY Dimers as Promising Photosensitizers for Antibacterial and Anticancer Treatment.

Porolnik W, Ratajczak M, Mackowiak A, Murias M, Kucinska M, Piskorz J Molecules. 2024; 29(22).

PMID: 39598693 PMC: 11596046. DOI: 10.3390/molecules29225304.


Tetrahydropyrimidine Ionizable Lipids for Efficient mRNA Delivery.

Isaac I, Shaikh A, Bhatia M, Liu Q, Park S, Bhattacharya C ACS Nano. 2024; 18(42):29045-29058.

PMID: 39393001 PMC: 11781979. DOI: 10.1021/acsnano.4c10154.


A Novel Tetrahydroacridine Derivative with Potent Acetylcholinesterase Inhibitory Properties and Dissociative Capability against Aβ42 Fibrils Confirmed by In Vitro Studies.

Mojzych I, Zawadzka A, Andrzejewski K, Jampolska M, Bednarikova Z, Gancar M Int J Mol Sci. 2024; 25(18).

PMID: 39337556 PMC: 11444201. DOI: 10.3390/ijms251810072.


References
1.
Li Y, Lee R, Yu K, Bi Y, Qi Y, Sun Y . Delivery of siRNA Using Lipid Nanoparticles Modified with Cell Penetrating Peptide. ACS Appl Mater Interfaces. 2016; 8(40):26613-26621. DOI: 10.1021/acsami.6b09991. View

2.
Radomska-Soukharev A . Stability of lipid excipients in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007; 59(6):411-8. DOI: 10.1016/j.addr.2007.04.004. View

3.
van der Meel R, Chen S, Zaifman J, Kulkarni J, Zhang X, Tam Y . Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery. Small. 2021; 17(37):e2103025. DOI: 10.1002/smll.202103025. View

4.
Scioli Montoto S, Muraca G, Ruiz M . Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects. Front Mol Biosci. 2020; 7:587997. PMC: 7662460. DOI: 10.3389/fmolb.2020.587997. View

5.
Sune-Pou M, Prieto-Sanchez S, El Yousfi Y, Boyero-Corral S, Nardi-Ricart A, Nofrerias-Roig I . Cholesteryl oleate-loaded cationic solid lipid nanoparticles as carriers for efficient gene-silencing therapy. Int J Nanomedicine. 2018; 13:3223-3233. PMC: 5985802. DOI: 10.2147/IJN.S158884. View